Search

everythinglearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.

Anti-CD19 therapy may help treat SLE and NMOSD.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Rituximab may cause skin issues, but baricitinib can help improve them.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Blocking α-toxin helps heal Staphylococcus aureus-infected wounds faster in both normal and diabetic mice, with different effects on their immune responses.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

Mast cells and VEGF contribute to post-surgery adhesions, and blocking VEGF can reduce these adhesions; also, certain factors affect wound healing and fetal skin heals differently with age.

The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.

A medication for skin rash also unexpectedly treated hair loss in a patient.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.

Dupilumab can both heal and cause hair loss.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Cetuximab can cause unusual hair growth and hair loss.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Antibody treatments show promise for hair loss but need more research.

Blocking interferon-gamma might help treat various autoimmune diseases.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.